Since the early stages of the COVID-19 vaccine rollout in the U.S., vaccine skeptics have used outdated interviews to spread claims that executives are refusing shots developed by their own ...

CLAIM: Video shows that the CEO of BioNTech, Dr. Ugur Sahin, will not take the COVID-19 vaccine that his firm developed with Pfizer. THE FACTS: Social media posts are misrepresenting an interview that ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine.

Side effects that have emerged in a large late-stage trial of a Covid-19 vaccine candidate from Pfizer Inc. and BioNTech SE are in line with those seen in smaller early studies, a positive sign for ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their ...

Pfizer and BioNTech are confident they can have a vaccine against the novel coronavirus ready for regulatory approval by the middle of October or early November, BioNTech CEO and co-founder Ugur Sahin ...

The chief medical officer of BioNTech told CNBC that people will likely need a third shot of its two-dose Covid-19 vaccine as immunity against the virus wanes. Dr. Ozlem Tureci, co-founder and CMO of ...

The chief executive of Germany's BioNTech SE said the biggest challenge facing it and partner Pfizer Inc now that their COVID-19 vaccine is authorized for use in the United States will be to scale up ...

Pfizer and BioNTech are testing a third dose of their Covid-19 vaccine to better understand the immune response against new variants of the virus. They are also in talks with regulatory authorities ...

The Chinese government has denied it obstructed Taiwan’s coronavirus vaccine purchase from BioNTech, after the island’s health minister revealed that its deal with the German drugmaker fell through at ...

Right before BioNTech was due to announce its 2025 results, the company’s co‑founders, Ugur Sahin and Özlem Türeci, revealed they would leave the company to focus on develop ...